Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in

Exopharm Ltd
ASX:EX1

Watchlist Manager
Exopharm Ltd Logo
Exopharm Ltd
ASX:EX1
Watchlist
Price: 0.023 AUD Market Closed
Market Cap: AU$1.6m
Write Note Create Alert Ask AI

Exopharm Ltd
Investor Relations

Exopharm Ltd. engages in the development and commercialization of exosomes as therapeutic agents. The company is headquartered in Melbourne, Victoria. The company went IPO on 2018-12-18. The firm is focused on developing and commercializing exosomes as therapeutic agents. The firm has three technologies that allows customization of exosomes, in which the LOAD technology improves loading of nucleic medicines into exosomes and the EVPS technology allows exosomes to be directed towards selected cell types. Its LEAP manufacturing technology provides access to exosomes for research and clinical uses. The firm is developing Engineered EVs (EEVs), are an emerging form of precision medicine with application in areas, such as neurology, cardiology and oncology. Its EEV projects under development are Fortrexo, Cognevo and PlexoDOX.

Show more
Loading
EX1
S&P/ASX 300
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Dr. Ian E. Dixon M.A.I.C.D., M.B.A., MBA, Ph.D.
Founder, Technology Co-Founder, CEO MD & Director
No Bio Available
Dr. Gregor Lichtfuss M.Sc.
Co-Founder & Business Services Manager
No Bio Available
Mr. Johannes Muhl
Senior Vice President of Finance
No Bio Available
Mr. David James Franks BEc, C.A., F Fin, J.P.
Company Secretary
No Bio Available

Contacts

Address
VICTORIA
Melbourne
Level 17/31 Queen St,
Contacts
+61391110026.0
exopharm.com
sparklesyt

See Also

Summary
EX1 intrinsic value, competitors valuation, and company profile.
DCF Valuation
EX1 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
EX1 stock valuation using valuation multiples.
Wall Street Estimates
EX1 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
EX1 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Back to Top
ALPHA SPREAD
Follow us
Join more than 314,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.